U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma - PubMed (original) (raw)

. 2013 Sep 1;19(17):4559-63.

doi: 10.1158/1078-0432.CCR-13-0755. Epub 2013 Jun 17.

Albert Deisseroth, Edvardas Kaminskas, Robert C Kane, Kallappa M Koti, Mark D Rothmann, Bahru Habtemariam, Julie Bullock, Jeffrey D Bray, Jessica Hawes, Todd R Palmby, Josephine Jee, William Adams, Houda Mahayni, Janice Brown, Angelica Dorantes, Rajeshwari Sridhara, Ann T Farrell, Richard Pazdur

Affiliations

U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma

Thomas M Herndon et al. Clin Cancer Res. 2013.

Abstract

The U.S. Food and Drug Administration (FDA) review leading to accelerated approval of carfilzomib is described. A single-arm trial enrolled 266 patients with multiple myeloma refractory to the most recent therapy who had received prior treatment with bortezomib and an immunomodulatory agent (IMID). Patients received carfilzomib by intravenous infusion over 2 to 10 minutes at a dose of 20 mg/m2 on days 1, 2, 8, 9, 15, and 16 of the 28 days of cycle 1, and at a dose of 27 mg/m2 on the same schedule in cycle 2 and subsequent cycles. The primary efficacy endpoint was overall response rate (ORR) as determined by an independent review committee using International Myeloma Working Group Uniform Response Criteria. The safety of carfilzomib was evaluated in 526 patients with multiple myeloma treated with various dosing regimens. The ORR was 23%. The median duration of response was 7.8 months. The most common adverse reactions associated with carfilzomib infusion were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and fever. The most common serious adverse events were pneumonia, acute renal failure, fever, and congestive heart failure. Infusion reactions to carfilzomib could be reduced by pretreatment with dexamethasone and intravenous fluids. On July 20, 2012, the FDA granted accelerated approval of carfilzomib for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an IMID and who have shown disease progression while on therapy or within 60 days of completion of the last therapy.

©2013 AACR.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources